Insider Trading April 7, 2026

Ulta Beauty Director Disposes of 452 Shares in April Transaction

George R. Mrkonic Jr. sells $243,759 of stock as analysts continue to offer mixed price targets and views

By Marcus Reed ULTA
Ulta Beauty Director Disposes of 452 Shares in April Transaction
ULTA

Ulta Beauty director George R. Mrkonic Jr. sold 452 shares of the company's common stock on April 7, 2026, for a weighted average price of $539.29, totaling $243,759. The sale, carried out by the company's chief legal officer under a power of attorney, leaves Mrkonic with 2,383 shares. Analysts continue to rate the stock favorably overall but offer divergent price targets and perspectives on near-term performance.

Key Points

  • Director George R. Mrkonic Jr. sold 452 Ulta Beauty shares on April 7, 2026, at a weighted average price of $539.29, totaling $243,759.
  • Post-transaction, Mrkonic directly holds 2,383 shares of Ulta Beauty, a company with a $23.3 billion market capitalization.
  • Analysts remain generally positive but differ on price targets and near-term outlooks - UBS ($810), Evercore ($675), Argus ($615) - while Jefferies discussed AI in beauty without naming Ulta.

Director George R. Mrkonic Jr. completed a sale of 452 shares of Ulta Beauty, Inc. (NASDAQ: ULTA) common stock on April 7, 2026, according to a Form 4 filed with the Securities and Exchange Commission.

The transaction was executed at a weighted average price of $539.29 per share, producing total proceeds of $243,759. Traded prices for the block ranged between $538.29 and $539.51.

Following the disposition, Mr. Mrkonic retains direct ownership of 2,383 Ulta Beauty shares. The company is currently valued at a market capitalization of $23.3 billion.

The sale was carried out by Rene G. Casares, Chief Legal Officer of Ulta Beauty, Inc., acting as attorney-in-fact for Mr. Mrkonic pursuant to a previously filed power of attorney, the Form 4 indicates.


Ulta stock has been trading below the transaction prices, quoted at $532.32 at the time of the filing. Over the last 12 months the shares have delivered a 58% total return, though recent performance has been softer. An InvestingPro analysis cited in the filing indicates the stock has performed poorly over the most recent month.

Institutional research and brokerage commentary included in the disclosure provide a range of perspectives on the company's outlook:

  • UBS reiterated a Buy rating on Ulta Beauty and set a $810 price target after a meeting with company executives, highlighting what the firm described as sustainable growth and characterizing the company's most recent fourth-quarter results as healthy, even if they did not surpass earlier earnings beats.
  • Evercore placed Ulta Beauty on its TAP Outperform List, maintaining an Outperform rating with a $675 price target and citing the company’s earnings potential despite recent pressures around expense discipline.
  • Argus reduced its price target from $700 to $615 but kept a Buy rating, suggesting the recent share weakness could offer an attractive entry point for investors.
  • Jefferies published commentary on how artificial intelligence is reshaping the beauty sector broadly; the firm’s note did not specifically mention Ulta Beauty.

Collectively, the analyst notes illustrate differing near-term assessments even as several firms retain constructive stances on the retailer’s longer-term prospects. The discussions also pointed to the recent decline in Ulta shares relative to broader market indexes.


Investors tracking insider activity will note that this sale was modest in size relative to Mr. Mrkonic’s remaining stake and to Ulta’s multi-billion-dollar market capitalization. The Form 4 confirms the mechanics of the trade and who executed it on the director’s behalf, but it does not provide additional commentary on the motivation for the transaction.

Risks

  • Near-term share weakness - The stock has performed poorly over the past month, per InvestingPro analysis, which could affect investor sentiment in the consumer discretionary and retail sectors.
  • Expense discipline concerns - Evercore cited challenges around expense control that could pressure profitability and operating metrics for the company.
  • Analyst divergence - Varied price targets and adjustments from research firms introduce uncertainty about consensus valuation and near-term upside for investors.

More from Insider Trading

Perdoceo General Counsel Sells $1.14 Million in Stock as Board Confirms 2026 Incentive Plan Apr 7, 2026 Cathay General Bancorp CEO Executes $243,505 Stock Sale Under 10b5-1 Plan Apr 7, 2026 Guardant Health Chief People Officer Disposes of $355K in Shares Amid Rising Stock Apr 7, 2026 Gladstone Commercial Executive Reports Small Share Purchase as Q4 Results Outperform Apr 7, 2026 Security National Financial Director Sells 10,000 Shares in $94,500 Transaction Apr 7, 2026